Prazosin for the Treatment of Behavioral Symptoms in Patients With Alzheimer Disease With Agitation and Aggression
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Objectives Agitation and aggression in Alzheimer’s disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine release may contribute to the pathophysiology of agitation and aggression in AD. Prazosin, a nonsedating generic medication used for hypertension and benign prostatic hypertrophy, antagonizes norepinephrine effects at brain postsynaptic alpha-1 adrenoreceptors. This pilot study examined the efficacy and tolerability of prazosin for behavioral symptoms in patients with agitation and aggression in AD. Design Double-blind, placebo controlled, parallel group study. Setting A university AD center and a nursing home in Seattle. Participants Twenty-two nursing home and community dwelling participants with agitation and aggression and probable or possible AD (mean age 80.6 ± 11.2). Intervention Randomization to placebo (n=11) or prazosin (n=11). Medication was initiated at 1mg/day and increased up to 6mg/day using a flexible dosing algorithm. Measurements The Brief Psychiatric Rating Scale (BPRS) and Neuropsychiatric Inventory (NPI) at weeks 1, 2, 4, 6, and 8. The Clinical Global Impression of Change (CGIC) at week 8. Results Participants taking prazosin (mean dose 5.7 ± 0.9mg/day) had greater improvements than those taking placebo (mean dose 5.6 ± 1.2mg/day) on the NPI (mean change -19 ± 21 versus -2 ± 15, X2=6.32, df=1, p=0.012) and BPRS (mean change -9 ± 9 versus -3 ± 5, X2=4.42, df=1, p=0.036) based on linear mixed effects models, and the CGIC (mean 2.6 ± 1.0 versus 4.5 ± 1.6, Z=2.57, p=0.011 [Mann-Whitney test]). Adverse effects and blood pressure changes were similar between prazosin and placebo groups. Conclusion Prazosin was well tolerated and improved behavioral symptoms in patients with agitation and aggression in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 1×
“Eligible participants had probable or possible AD by the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer’s Disease and Related Disorders Association criteria and exhibited agitation/aggression at least twice weekly for 2 weeks, with a score of 4 (moderate) or more on at least on…”
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
A Description of Agitation in a Nursing Home
Cohen-mansfield, J., Marx, M. S., & Rosenthal, A. S. (1989) · Journal of Gerontology · doi:10.1093/geronj/44.3.m77 · Cited by 1,349
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206 · cited 1×
“The Clinical Antipsychotic Trials of Intervention Effectiveness— Alzheimer Disease (CATIE-AD) study showed that side effects, such as sedation, extrapyramidal symptoms, and confusion, often offset efficacy of atypical antipsychotics for patients with AD with agitation/ aggression.(12) It has been hypothesized that sed…”
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
Schneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
The Impact of Dementia on the Family
Rabins, P. V. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03330030039022 · Cited by 755
Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.8.1049 · Cited by 744 · cited 1×
“Agitation/aggression increases caregiver burden in both the home and the long-term care setting, is distressing to patients and others in the patient’s environment,(4,5) and is a frequent precipitant of long-term care placement.(6) Treatment guidelines recommend the use of atypical antipsychotics to reduce agitation/a…”
Katz, I. R., Jeste, D. V., Mintzer, J. E., Clyde, C., Napolitano, J., Brecher, M., & The Risperidone Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0207 · Cited by 741
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 647
Binding of antipsychotic drugs to human brain receptors
Richelson, E., & Souder, T. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00911-5 · Cited by 607 · cited 2×
“Olanzapine, risperidone, and ziprasidone are comparably potent at the alpha-1 AR and dopamine D2 receptor.(36) Recently, representatives from academic medical centers, the pharmaceutical industry, the FDA, National Institutes of Health (NIH), the nursing home industry, and patient advocacy groups created a consensus s…”
Street, J. S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.968 · Cited by 590
Troublesome and Disruptive Behaviors in Dementia: Relationships to Diagnosis and Disease Severity
Swearer, J. M., Drachman, D. A., O'Donnell, B. F., & Mitchell, A. L. (1988) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1988.tb04260.x · Cited by 356
Introduction: Methods, Commentary, and Summary
Alexopoulos, G. S., Streim, J. E., Carpenter, D. P., & Docherty, J. P. (2004) · The Journal of Clinical Psychiatry · Cited by 336
Using antipsychotic agents in older patients.
Alexopoulos, G. S., Streim, J. E., Carpenter, D., & Docherty, J. P. (2004) · PubMed · Cited by 327
Sultzer, D. L., Davis, S. M., Tariot, P. N., Dagerman, K. S., Lebowitz, B. D., Lyketsos, C. G., Rosenheck, R. A., Hsiao, J. K., Lieberman, J. A., Schneider, L. S., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111779 · Cited by 321 · cited 1×
“The magnitude of behavioral improvement with prazosin in this study was comparable with that of atypical antipsychotics in previous randomized controlled trials.(10,13,14,32,33) Because there is substantial loss of NE producing locus ceruleus (LC) neurons in AD, it may seem counterintuitive that reducing the CNS posts…”
Ballard, C., Margallo-Lana, M., Juszczak, E., Douglas, S., Swann, A., Thomas, A., O'Brien, J., Everratt, A., Sadler, S., Maddison, C., et al. (2005) · BMJ · doi:10.1136/bmj.38369.459988.8f · Cited by 315 · cited 1×
“Previous studies of propranolol and atypical antipsychotics that include longer observational periods indicate that behavioral improvements may not persist long term.(39,40) Longer follow-up in future studies would better establish longterm efficacy.”
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Ferris, S. H., Schmitt, F. A., Grundman, M., & Thomas, R. G. (1997) · Alzheimer Disease · doi:10.1007/978-1-4612-4116-4_64 · Cited by 303
Lyketsos, C. G., Colenda, C. C., Beck, C., Blank, K., Doraiswamy, M. P., Kalunian, D. A., & Yaffe, K. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000221334.65330.55 · Cited by 275 · cited 1×
“Several consensus guidelines and position statements recommend using atypical antipsychotics when nonpharmacological approaches have failed, but they caution prescribers about the increased side effect burden and risks involved, including the FDA “black box warning” for risk of cerebrovascular events and mortality in…”
Szot, P., White, S. S., Greenup, J. L., Leverenz, J. B., Peskind, E. R., & Raskind, M. A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4265-05.2006 · Cited by 248 · cited 1×
“In addition to the compensatory upregulation of presynaptic noradrenergic outflow in AD, there is also increased density of postsynaptic alpha-1 AR in LC projection areas in prefrontal cortex and hippocampus.(21,22) This upregulation of postsynaptic alpha-1 AR is associated with aggressive behavior antemortem.”
Self-citationSalzman, C., Jeste, D. V., Meyer, R. E., Cohen-Mansfield, J., Cummings, J., Grossberg, G. T., Jarvick, L., Kraemer, H. C., Lebowitz, B. D., Maslow, K., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0602 · Cited by 229 · cited 2×
“Recently, representatives from academic medical centers, the pharmaceutical industry, the FDA, National Institutes of Health (NIH), the nursing home industry, and patient advocacy groups created a consensus statement stressing the need for medications to treat agitation related to dementia and the drawbacks of current…”
Self-citationTariot, P. N., Schneider, L. S. S., Katz, I. R., Mintzer, J. E., Street, J. S., Copenhaver, M. D., & Williams-Hughes, C. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000196628.12010.35 · Cited by 155 · cited 1×
“The magnitude of behavioral improvement with prazosin in this study was comparable with that of atypical antipsychotics in previous randomized controlled trials.(10,13,14,32,33) Because there is substantial loss of NE producing locus ceruleus (LC) neurons in AD, it may seem counterintuitive that reducing the CNS posts…”
Selbæk, G., Kirkevold, Ø., & Engedal, K. (2008) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318167ae76 · Cited by 154
Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.1.25 · Cited by 140 · cited 1×
“However, compensatory upregulation of surviving LC neurons that sustain ageappropriate enhanced levels of CNS NE outflow in AD is supported by multiple postmortem brain tissue and clinical studies.(19,20,34) In addition to the compensatory upregulation of presynaptic noradrenergic outflow in AD, there is also increase…”
Peskind, E. R., Tsuang, D. W., Bonner, L. T., Pascualy, M., Riekse, R. G., Snowden, M. B., Thomas, R. G., & Raskind, M. A. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000155067.16313.5e · Cited by 134 · cited 1×
“Previous studies of propranolol and atypical antipsychotics that include longer observational periods indicate that behavioral improvements may not persist long term.(39,40) Longer follow-up in future studies would better establish longterm efficacy.”
Self-citationPrazosin selectively antagonizes neuronal responses mediated by ?1-adrenoceptors in brain
Menkes, D. B., Baraban, J. M., & Aghajanian, G. K. (1981) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00503830 · Cited by 129 · cited 1×
“It is the only clinically available alpha-1 AR antagonist that readily crosses from the blood into brain; it has been demonstrated specifically to block CNS alpha-1 ARs when administered peripherally.(23,24) In an open label study of persons with AD and treatment-resistant agitation, prazosin administration was associ…”
Streim, J. E., Porsteinsson, A. P., Breder, C. D., Swanink, R., Marcus, R. N., McQuade, R. D., & Carson, W. H. (2008) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318165db77 · Cited by 127 · cited 1×
“The magnitude of behavioral improvement with prazosin in this study was comparable with that of atypical antipsychotics in previous randomized controlled trials.(10,13,14,32,33) Because there is substantial loss of NE producing locus ceruleus (LC) neurons in AD, it may seem counterintuitive that reducing the CNS posts…”
Unmet need for services and interventions among adolescents with mental disorders
Wang, P. S., Sherrill, J., & Vitiello, B. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.1 · Cited by 123
Szot, P., White, S., Greenup, J., Leverenz, J., Peskind, E., & Raskind, M. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.01.031 · Cited by 103 · cited 1×
“In addition to the compensatory upregulation of presynaptic noradrenergic outflow in AD, there is also increased density of postsynaptic alpha-1 AR in LC projection areas in prefrontal cortex and hippocampus.(21,22) This upregulation of postsynaptic alpha-1 AR is associated with aggressive behavior antemortem.”
Self-citationPeskind, E. R. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950210068012 · Cited by 100 · cited 1×
“However, compensatory upregulation of surviving LC neurons that sustain ageappropriate enhanced levels of CNS NE outflow in AD is supported by multiple postmortem brain tissue and clinical studies.(19,20,34) In addition to the compensatory upregulation of presynaptic noradrenergic outflow in AD, there is also increase…”
Self-citationSchneider, G., Driesch, G., Kruse, A., Nehen, H.-G., & Heuft, G. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000233784.04532.a5 · Cited by 98
Sharp, S. I., Ballard, C. G., Chen, C., & Francis, P. T. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000237065.78966.1b · Cited by 49 · cited 1×
“This upregulation of postsynaptic alpha-1 AR is associated with aggressive behavior antemortem.(35) That antagonism of brain alpha-1 AR by prazosin reduces behavioral symptoms in AD is, therefore, consistent with the complex neurobiology of brain adrenergic system changes in AD.”
Kryzhanovskaya, L. A., Jeste, D. V., Young, C. A., Polzer, J. P., Roddy, T. E., Jansen, J. F., Carlson, J. L., & Cavazzoni, P. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0610 · Cited by 42 · cited 1×
“It has been hypothesized that sedation caused by antipsychotics may increase morbidity and mortality in frail elderly patients with dementia.(11,38) Prazosin is a promising treatment alternative because it is rarely sedating.”
Agitation and Psychosis in Dementia
Ballard, C. G. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181584268 · Cited by 22 · cited 1×
“It has been hypothesized that sedation caused by antipsychotics may increase morbidity and mortality in frail elderly patients with dementia.(11,38) Prazosin is a promising treatment alternative because it is rarely sedating.”
Increased activity of surviving locus ceruleus neurons in Alzheimer's disease
Moser (1999) · Pure Amsterdam UMC · doi:10.1002/1531-8249(199901)45:1 · cited 1×
“However, compensatory upregulation of surviving LC neurons that sustain ageappropriate enhanced levels of CNS NE outflow in AD is supported by multiple postmortem brain tissue and clinical studies.(19,20,34) In addition to the compensatory upregulation of presynaptic noradrenergic outflow in AD, there is also increase…”
Cited by
Assessment and management of behavioral and psychological symptoms of dementia
Kales, H. C., Gitlin, L. N., & Lyketsos, C. G. (2015) · BMJ · doi:10.1136/bmj.h369 · Cited by 1,247
Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease
Weinshenker, D. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.01.010 · Cited by 323
Monoaminergic neuropathology in Alzheimer’s disease
Šimić, G., Babić Leko, M., Wray, S., Harrington, C. R., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., de Silva, R., Di Giovanni, G., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.001 · Cited by 289
Management of Behavioral and Psychological Symptoms of Dementia
Bessey, L. J., & Walaszek, A. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1049-5 · Cited by 288
New approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226
Metadata
- Authors
- Wang, L. Y., Shofer, J. B., Rohde, K., Hart, K. L., Hoff, D. J., McFall, Y. H., Raskind, M. A., & Peskind, E. R.
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 17
- Issue
- 9
- Pages
- 744-751
- ISSN
- 1064-7481 (ISSN-L)
- OpenAlex
- W2003816877
- Cited by
- 209
- References
- 42
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.